

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The ongoing Phase III THOR trial is investigating which of the following agents in comparison to docetaxel, vinflunine or pembrolizumab for patients with advanced urothelial cancer harboring FGFR alterations?**

 - Enfortumab vedotin
 - Erdafitinib**
 - Cetrelimab
 - Tremelimumab
- 2. Which of the following drug descriptions best reflects the mechanism of action of sacituzumab govitecan?**

 - Antibody-drug conjugate (ADC) targeting nectin-4
 - ADC targeting TROP2**
 - ADC targeting FGFR
 - PD-1/PD-L1 inhibitor
 - FGFR inhibitor
- 3. In the Phase III DANUBE trial, investigating durvalumab alone or in combination with tremelimumab as first-line therapy for patients with unresectable Stage IV bladder cancer, which of the following overall survival outcomes has been reported in comparison to standard chemotherapy?**

 - Statistically significant improvement on the durvalumab/tremelimumab study arm only
 - Statistically significant improvement on the durvalumab monotherapy arm only
 - Statistically significant improvement on both the durvalumab/tremelimumab and the durvalumab monotherapy arms
 - No statistically significant difference between durvalumab/tremelimumab and durvalumab monotherapy**
- 4. Of the following toxicities, which were the most frequently experienced by patients who received enfortumab vedotin for previously treated locally advanced or metastatic urothelial bladder cancer on the Phase II EV-201 trial?**

 - Hypertension and myocardial ischemia
 - Thrombocytopenia, pneumonitis and diarrhea
 - Skin reactions, hyperglycemia and peripheral neuropathy**
- 5. Which of the following overall survival outcomes was reported for patients who received maintenance treatment with avelumab and best supportive care (BSC) or BSC alone for unresectable locally advanced or metastatic urothelial cancer after first-line chemotherapy in the Phase III JAVELIN Bladder 100 trial?**

 - A statistically significant improvement with avelumab and BSC compared to BSC alone for only those patients with PD-L1-high tumors
 - A statistically significant improvement with avelumab and BSC compared to BSC alone both in the overall population and in the PD-L1-high population**
 - No statistically significant improvement with avelumab and BSC compared to BSC alone